Patents Assigned to Nippon Shinyaku Co., Ltd.
-
Patent number: 11781140Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.Type: GrantFiled: August 25, 2022Date of Patent: October 10, 2023Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yu Honda, Kaname Muchima, Takahiro Fukui, Saki Hasegawa, Shin'ichi Takeda, Yoshitsugu Aoki
-
Publication number: 20230303500Abstract: A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5, 6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2?) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 Å) . A form-II crystal of Compound B, which shows peaks at diffraction angles (2?) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 Å) .Type: ApplicationFiled: April 12, 2023Publication date: September 28, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventor: Toshio FUJIWARA
-
Publication number: 20230250083Abstract: A main object of the present invention is to provide new crystals of (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate (hereinafter, referred to as “compound A”). A Form-I crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2?: 6.9 degrees, 9.4 degrees, 12.5 degrees, 15.1 degrees, 16.4 degrees, 18.3 degrees, 19.0 degrees, 24.9 degrees, 25.4 degrees, 27.3 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu K? radiation (?=1.54 ?). A Form-II crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2?: 6.9 degrees, 9.2 degrees, 12.4 degrees, 14.8 degrees, 16.5 degrees, 18.1 degrees, 18.5 degrees, 19.8 degrees, 23.6 degrees, 24.9 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu K? radiation (?=1.Type: ApplicationFiled: April 13, 2023Publication date: August 10, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Toshio FUJIWARA, Joanna BIS, Senthil Kumar Kusalakumari SUKUMAR
-
Patent number: 11680055Abstract: A main object of the present invention is to provide new crystals of (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate (hereinafter, referred to as “compound A”). A Form-I crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2?: 6.9 degrees, 9.4 degrees, 12.5 degrees, 15.1 degrees, 16.4 degrees, 18.3 degrees, 19.0 degrees, 24.9 degrees, 25.4 degrees, 27.3 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu K? radiation (?=1.54 ?). A Form-II crystal of the compound A, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2?: 6.9 degrees, 9.2 degrees, 12.4 degrees, 14.8 degrees, 16.5 degrees, 18.1 degrees, 18.5 degrees, 19.8 degrees, 23.6 degrees, 24.9 degrees, and 27.7 degrees, wherein X-ray powder diffraction spectrum is obtained by using Cu K? radiation (?=1.Type: GrantFiled: September 27, 2018Date of Patent: June 20, 2023Assignee: NIPPON SHINYAKU CO., LTD.Inventors: Toshio Fujiwara, Joanna Bis, Senthil Kumar Kusalakumari Sukumar
-
Patent number: 11655218Abstract: A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2?) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 ?). A form-II crystal of Compound B, which shows peaks at diffraction angles (2?) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-K? radiation (?=1.54 ?).Type: GrantFiled: December 28, 2020Date of Patent: May 23, 2023Assignee: NIPPON SHINYAKU CO., LTD.Inventor: Toshio Fujiwara
-
Patent number: 11655472Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.Type: GrantFiled: June 23, 2022Date of Patent: May 23, 2023Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yukiko Enya, Yuta Sunadoi, Reiko Waki, Kaname Muchima, Shin'ichi Takeda, Yoshitsugu Aoki
-
Publication number: 20230151050Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: November 8, 2022Publication date: May 18, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20230140736Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.Type: ApplicationFiled: February 26, 2021Publication date: May 4, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yu HONDA, Kaname MUCHIMA, Takahiro FUKUI, Saki HASEGAWA, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20230094705Abstract: The present invention relates to a prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome, the agent containing an mPGES-1 inhibitor as an active ingredient.Type: ApplicationFiled: December 24, 2020Publication date: March 30, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Ken OKAMOTO, Maki KURITA, Hiroshi YAMAGUCHI
-
Publication number: 20230101484Abstract: An object of the present invention is to provide a compound having a PDGF receptor kinase inhibitory activity. Examples of the present invention may include, for example, a compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof. The compound of the present invention has an inhibitory activity against the PDGF receptor kinase. In addition, since the compound of the present invention has an inhibitory activity against the PDGF receptor kinase, it is useful as a therapeutic agent for respiratory diseases, cancers, smooth muscle proliferative diseases, vasoproliferative diseases, autoimmune/inflammatory diseases, metabolic diseases, vasoocclusive diseases, and the like.Type: ApplicationFiled: December 11, 2020Publication date: March 30, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Junshi ASADA, Yoshinari HARUTA, Hiroyuki YAKUSHIJI, Toru TANAKA, Kazuya KURAMOTO, Keiji KOSUGI, Chiaki FUCHIKAMI
-
Publication number: 20230097387Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.Type: ApplicationFiled: August 25, 2022Publication date: March 30, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yu HONDA, Kaname MUCHIMA, Takahiro FUKUI, Saki HASEGAWA, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20230073008Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.Type: ApplicationFiled: December 25, 2020Publication date: March 9, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20230045557Abstract: The present specification provides an antisense oligomer capable of causing simultaneous skipping of a plurality of exons in pre-mRNA of interest, and a pharmaceutical composition comprising the oligomer. The present specification also provides an antisense oligomer or a pharmaceutically acceptable salt thereof, or hydrate thereof which causes simultaneous skipping of two or more numerically consecutive exons from pre-mRNA of interest, the antisense oligomer comprising a base sequence complementary to a base sequence of a region including the vicinity of a donor of any intron in the pre-mRNA of interest, or a region including the vicinity of an acceptor of any intron in the pre-mRNA of interest, or a partial base sequence thereof.Type: ApplicationFiled: December 18, 2020Publication date: February 9, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20230040402Abstract: The present invention relates to a prophylactic and/or therapeutic agent for cancer containing an mPGES-1 inhibitor as an active ingredient, the agent being useful in combination with an immune checkpoint inhibitor, and the invention has industrial applicability.Type: ApplicationFiled: December 24, 2020Publication date: February 9, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Keiji KOSUGI, Toshiyuki MINAMI, Shiho IWASAKI, Itaru YAMAMOTO
-
Patent number: 11560401Abstract: A method for subjecting a compound [A] having a hydroxyl group or a primary or secondary amino group and a compound [B] having a substituent containing a phosphorus atom to a condensation reaction to prepare a compound [C] represented by the following general formula [C]: wherein the condensation reaction is carried out in a mixed solvent containing a polar solvent and a halogen solvent as a reaction solvent.Type: GrantFiled: May 10, 2019Date of Patent: January 24, 2023Assignee: NIPPON SHINYAKU CO., LTD.Inventors: Yutaro Kotobuki, Fumiya Urabe
-
Publication number: 20230014840Abstract: The present invention relates to a method for producing a compound represented by general formula [C-1-1], which comprises: a step for reacting a compound represented by general formula [B-1-1] with a compound represented by general formula [P] to form a compound represented by general formula [B-1-2]; and a step for reacting the compound represented by general formula [B-1-2] with a compound represented by general formula [A-1] to form the compound represented by general formula [C-1-1].Type: ApplicationFiled: November 13, 2020Publication date: January 19, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Yutaro KOTOBUKI, Koki KATO
-
Publication number: 20230018780Abstract: The present invention relates to a method for producing a compound [C] of the general formula [C] by subjecting a compound [A] having a hydroxyl group or a primary or secondary amino group and a compound [B] having a phosphorous atom-containing substituent group of the general formula [1] to a condensation reaction, characterized in that the method is carried out in the presence of at least one reaction accelerator selected from the group consisting of a quaternary ammonium salt, a quaternary imidazolium salt, a quaternary morpholinium salt, a quaternary phosphonium salt, a quaternary piperidinium salt, a quaternary pyridinium salt, a quaternary pyrrolidinium salt and a quaternary sulfonium salt.Type: ApplicationFiled: November 13, 2020Publication date: January 19, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventor: Junshi ASADA
-
Publication number: 20230002395Abstract: The purpose of the present invention is to provide a compound having M3 PAM activity. Examples of the present invention include azabenzimidazole compounds represented by the following formula [1] and pharmaceutically acceptable salts thereof. The compounds of the present invention have M3 PAM activity. In addition, since the compounds of the present invention have M3 PAM activity, the compounds of the present invention are useful as preventive agents or therapeutic agents for urination disorders and urine collection disorders in underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, and neurogenic bladder.Type: ApplicationFiled: November 12, 2020Publication date: January 5, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Koya OIKAWA, Takuto YAMANAKA, Sho HIRAI, Kazuhiko WAKITA
-
Publication number: 20230000840Abstract: A novel prophylactic agent or therapeutic agent for functional gastrointestinal disorders or xerostomia is provided. The present invention is a therapeutic agent or prophylactic agent for functional gastrointestinal disorders, containing an azabenzimidazole compound represented by the following formula [1] (each symbol in the formula is as described in the specification), or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.Type: ApplicationFiled: November 12, 2020Publication date: January 5, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Ryohei YOSHINAGA, Maki KURITA, Yasunori ASAO, Tomomi FUKUI
-
Publication number: 20220333112Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.Type: ApplicationFiled: June 23, 2022Publication date: October 20, 2022Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI